Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160012 | 0.91 | L3MBTL1 (0.42) | L3MBTL1TDP1GAATLR8MCHR1 | |
| SCHEMBL27501834 | 0.89 | L3MBTL1 (0.45) | L3MBTL1TDP1MAPTALDH1A1KDM4E | |
| SCHEMBL27294182 | 0.88 | L3MBTL1 (0.44) | L3MBTL1TDP1MAPTALDH1A1MEN1 | |
| SCHEMBL1228883 | 0.88 | L3MBTL1 (0.44) | L3MBTL1TDP1MAPTALDH1A1MEN1 | |
| SCHEMBL9699956 | 0.88 | L3MBTL1 (0.44) | L3MBTL1TDP1MAPTALDH1A1MEN1 | |
| SCHEMBL9699861 | 0.88 | L3MBTL1 (0.44) | L3MBTL1TDP1MAPTALDH1A1MEN1 | |
| SCHEMBL14814379 | 0.85 | L3MBTL1 (0.40) | L3MBTL1TDP1MAPTALDH1A1KDM4E | |
| SCHEMBL161774 | 0.85 | L3MBTL1 (0.46) | L3MBTL1TDP1MAPTALDH1A1KDM4E | |
| SCHEMBL21268193 | 0.84 | L3MBTL1 (0.39) | L3MBTL1TDP1ALDH1A1KDM4EMEN1 | |
| SCHEMBL687572 | 0.82 | MAPT (0.39) | L3MBTL1MAPTALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| US-7915258-B2 | Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one derivatives, preparation thereof and therapeutic use of the same | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | claimed |
| EP-2094706-B1 | SUBSTITUTED 2,5-DFFLYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND USE OF SAME AS CANNABINOID CB1 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2011-01-05 | — | — | EP | claimed |
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | claimed |
| CN-101541802-A | Substituted 2, 5-dihydro-3H-pyrazolo [4, 3-C ] pyridazin-3-one derivatives, preparation thereof and use thereof in therapy | SANOFI AVENTIS (FR) | 2009-09-23 | — | — | CN | claimed |
| EP-0888340-B1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2002-07-17 | — | — | EP | claimed |
| CN-1356988-A | Phenoxy fluoropyrimidines | BAYER AG (DE) | 2002-07-03 | — | — | CN | claimed |
| CN-1079397-C | 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives endothelin antagonists | ABBOTT LAB (US) | 2002-02-20 | — | — | CN | claimed |
| US-6124341-A | A DRUG FOR TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, RESTENOSIS FOLLOWING ARTERIAL INJURY, CEREBRAL OR MYOCARDIAL ISCHEMIA OR ATHEROSCLEROSIS; VASODILUTOR | ABBOTT LABORATORIES (US) | 2000-09-26 | — | — | US | claimed |
| CN-1265097-A | Pyrrolidine carboxylic acid derivatives as endothelin antagonists | ABBOTT LAB (US) | 2000-08-30 | — | — | CN | claimed |
| EP-0991620-A1 | PYRROLIDINE CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 2000-04-12 | — | — | EP | claimed |
| CN-1215401-A | 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives endothelin antagonists | ABBOTT LAB (US) | 1999-04-28 | — | — | CN | claimed |
| EP-0888340-A1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1998057933-A1 | PYRROLIDINE CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1997030046-A1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | DHFR, DPYD, QDPR | L3MBTL1 4466/4885TDP1 1929/4885MAPT 3119/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 3563/4885TDP1 3947/4885MAPT 519/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 3563/4885TDP1 3947/4885MAPT 519/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 2990/4885TDP1 3665/4885MAPT 268/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 2990/4885TDP1 3665/4885MAPT 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.